Why the study?
Does levosimendan improve clinical and hemodynamic outcomes in patients with acute heart failure or cardiogenic shock complicating acute coronary syndrome?
Does levosimendan improve clinical and hemodynamic outcomes in patients with acute heart failure or cardiogenic shock complicating acute coronary syndrome?
An expert consensus panel recommends levosimendan as a preferred inodilator for acute heart failure complicating ACS, particularly in patients on beta-blockers, due to its favorable hemodynamic and cardioprotective profile.
Answers are grounded in this paper and cite their sources.
May support levosimendan preference in select ACS shock cases; leaves open confirmation by prospective RCTs.
Acute heart failure and/or cardiogenic shock are frequently triggered by ischemic coronary events. Yet, there is a paucity of randomized data on the management of patients with heart failure complicating acute coronary syndrome, as acute coronary syndrome and cardiogenic shock have frequently been defined as exclusion criteria in trials and registries. As a consequence, guideline recommendations are mostly driven by observational studies, even though these patients have a particularly poor prognosis compared to heart failure patients without signs of coronary artery disease. In acute heart failure, and especially in cardiogenic shock related to ischemic conditions, vasopressors and inotropes are used. However, both pathophysiological considerations and available clinical data suggest that these treatments may have disadvantageous effects. The inodilator levosimendan offers potential benefits due to a range of distinct effects including positive inotropy, restoration of ventriculo-arterial coupling, increases in tissue perfusion, and anti-stunning and anti-inflammatory effects. In clinical trials levosimendan improves symptoms, cardiac function, hemodynamics, and end-organ function. Adverse effects are generally less common than with other inotropic and vasoactive therapies, with the notable exception of hypotension. The decision to use levosimendan, in terms of timing and dosing, is influenced by the presence of pulmonary congestion, and blood pressure measurements. Levosimendan should be preferred over adrenergic inotropes as a first line therapy for all ACS-AHF patients who are under beta-blockade and/or when urinary output is insufficient after diuretics. Levosimendan can be used alone or in combination with other inotropic or vasopressor agents, but requires monitoring due to the risk of hypotension.
No takes yet. Share an insight, caveat, or question.
Nieminen et al. (2016) conducted a review in Acute heart failure and cardiogenic shock complicating acute coronary syndrome. Levosimendan was evaluated. Levosimendan offers potential benefits in treating acute heart failure and cardiogenic shock complicating acute coronary syndrome and should be preferred over adrenergic inotropes as a first-line therapy in specific patients.
Synapse has enriched 10 related papers. Consider them for comparative context: